Literature DB >> 28589397

Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.

Michele Colicchia1, Vidit Sharma1, Firas Abdollah2, Alberto Briganti3, R Jeffrey Karnes4.   

Abstract

Extent of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) remains a subject of debate. Here, we review the literature covering the value of extended PLND (ePLND) during RP for high-risk prostate cancer (PCa) over a standard PLND, with a focus on potential therapeutic advantage. PLND may provide valuable prognostic information to high-risk PCa patients, and incorporating the common iliac and presacral nodes to ePLND templates further improves pathologic nodal staging accuracy. Although increased PLND extent is associated with increased lymphocele/lymphedema rates, it is not associated with increased venous thromboembolism rates. The therapeutic role of ePLND remains uncertain. While recent retrospective studies suggest an increased number of nodes removed within the ePLND template are associated with improved survival outcomes, such retrospective studies cannot completely adjust for the Will Rodgers phenomenon or surgeon-specific factors. Thus, the results of randomized trials are eagerly awaited in this arena.

Entities:  

Keywords:  Extended lymphadenectomy; Pelvic lymphadenectomy; Prostate cancer; Radical prostatectomy

Mesh:

Year:  2017        PMID: 28589397     DOI: 10.1007/s11934-017-0696-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  38 in total

1.  Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study.

Authors:  Jindong Ji; Hexing Yuan; Liangliang Wang; Jianquan Hou
Journal:  J Surg Res       Date:  2012-07-17       Impact factor: 2.192

2.  Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212-9: Extended Lymph Node Dissection and the Will Rogers Phenomenon.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Eur Urol       Date:  2014-10-03       Impact factor: 20.096

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  A nomogram predicting prostate cancer-specific mortality after radical prostatectomy.

Authors:  Christopher R Porter; Nazareno Suardi; Umberto Capitanio; Georg C Hutterer; Koichi Kodama; Robert P Gibbons; Roy Correa; Paul Perrotte; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Urol Int       Date:  2010-03-04       Impact factor: 2.089

5.  Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum.

Authors:  Alberto Briganti; Nazareno Suardi; Paolo Capogrosso; Niccolò Passoni; Massimo Freschi; Ettore di Trapani; Andrea Gallina; Umberto Capitanio; Firas Abdollah; Manuela Tutolo; Marco Bianchi; Andrea Salonia; Luigi Filippo Da Pozzo; Francesco Montorsi; Patrizio Rigatti
Journal:  Prostate       Date:  2011-05-02       Impact factor: 4.104

6.  Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.

Authors:  Tom Budiharto; Steven Joniau; Evelyne Lerut; Laura Van den Bergh; Felix Mottaghy; Christophe M Deroose; Raymond Oyen; Filip Ameye; Kris Bogaerts; Karin Haustermans; Hendrik Van Poppel
Journal:  Eur Urol       Date:  2011-01-18       Impact factor: 20.096

7.  Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques.

Authors:  N N Stone; R G Stock; P Unger
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

8.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  High-risk prostate cancer in the United States, 1990-2007.

Authors:  Matthew R Cooperberg; Janet Cowan; Jeannette M Broering; Peter R Carroll
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226

10.  More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.

Authors:  Firas Abdollah; Giorgio Gandaglia; Nazareno Suardi; Umberto Capitanio; Andrea Salonia; Alessandro Nini; Marco Moschini; Maxine Sun; Pierre I Karakiewicz; Sharhokh F Shariat; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2014-06-02       Impact factor: 20.096

View more
  1 in total

1.  Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.

Authors:  Teppei Matsumoto; Shingo Hatakeyama; Teppei Ookubo; Koji Mitsuzuka; Shintaro Narita; Takamitsu Inoue; Shinichi Yamashita; Takuma Narita; Takuya Koie; Sadafumi Kawamura; Tatsuo Tochigi; Norihiko Tsuchiya; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama
Journal:  Med Oncol       Date:  2017-10-31       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.